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these areas.11 An examination of the Massachusetts
law illustrates the main areas of concern, how political
compromises can undermine the best intentions, and
the limits of state privacy and antidiscrimination laws
governing genetic information. All state legislation
presumes that genetic information requires special
protection; whether this presumption is valid is itself
a point of contention.12
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URING the 2000 presidential campaign, Al
Gore characterized the DNA code as a secret
code like that of the Nazis. In his words, “with
the completion of the Human Genome, we are on the
verge of cracking another enemy’s secret code. When
we intercept and decipher the coded messages that
cancer sends from cell to cell, we will turn the tide, and
win the war against cancer.”1 Gore was expanding the
metaphor of the war on cancer, and commandeering
the DNA code in the service of that metaphor. At
about the same time, then president Bill Clinton called
the DNA code “the language in which God created
life.”2 The metaphors we use to describe a thing profoundly affect how we think about it. A variety of metaphors have been used to describe human DNA, including “the book of life,” the “book of man,” “the
holy grail of biology,” and the “blueprint of life.”3
Metaphors both inform and misinform, since they
represent one thing as another.4 Given the proliferation of secret-code metaphors and hyperbolic religious
metaphors for the human genome, it is not surprising that there is great concern about how to protect
personal DNA information, including genetic variations that predispose a person to various diseases, such
as breast cancer. I have suggested elsewhere that a
person’s DNA can usefully be viewed as a coded “future diary” and that it should be considered as personal and private as a diary about that person’s past.5,6 In
1995, my colleagues and I proposed a federal geneticprivacy act for the Human Genome Project.7,8 However, other than the inclusion of the undefined term
“genetic information” as something group health plans
cannot use to deny eligibility under the Health Insurance Portability and Accountability Act of 1996, no
federal legislation has been enacted. In the absence of
federal legislation, the states have had to act on their
own to protect the privacy of individual genetic information and to protect against discrimination on the
basis of such information. Most states now prohibit
discrimination on the basis of genetic information in
one or more types of insurance, about half prohibit
such discrimination in employment, and more than a
dozen require informed consent before a genetic test
can be performed.9,10 One of the most recent state
laws, enacted in Massachusetts in 2000, covers all
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THE MASSACHUSETTS
GENETIC-TESTING LAW

The Massachusetts law is designed to protect persons from discrimination based on the results of genetic testing. The law requires that informed consent be
obtained before most genetic tests are performed and
prohibits employers and some insurers from requiring
genetic testing or using the results of such testing in
a discriminatory fashion.11 The protected genetic information generally includes “any written or recorded
individually identifiable result of a genetic test . . . or
explanation of such a result.” Thus, the definition of
“genetic test” is central, and in the law this definition
varies depending on the entity involved. A genetic test
is defined as “a test of human DNA, RNA, mitochondrial DNA, chromosomes, or proteins for the purpose
of identifying genes, inherited or acquired genetic abnormalities, or the presence or absence of inherited or
acquired characteristics in genetic material.”11
Written informed consent is required before conducting a genetic test or divulging its results. The informed-consent document must contain the following
information: a statement of the purpose of the test; a
statement that the person being asked to provide consent has been informed of the reliability of positive or
negative test results and the level of certainty that a
positive result serves as a predictor of the condition in
question; a statement that the person has been informed of the availability and importance of genetic
counseling and has been given, in writing, the name
of a genetic counselor or medical geneticist who will
provide such counseling; and a general description of
each specific condition tested for and the person or
persons to whom the test results may be disclosed.11
The requirement to obtain informed consent does
not apply to genetic testing performed by physicians
or hospitals for diagnostic purposes. For health insurers and health maintenance organizations (HMOs),
however, informed consent is required for both predictive and diagnostic tests. A narrower definition of genetic information applies to disability and life insurance
companies, and a broader definition (including family
history) applies to employers.
The informed-consent requirement is also not applicable to newborn screening and tests for drugs, alcohol, cholesterol, or antibodies to the human immunodeficiency virus when these tests are performed
by physicians or hospitals. Each of these exceptions
reflects successful lobbying on the part of interest
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groups. There is also a specific exception to reobtaining consent for “pharmaco-economic” research to determine the cost–benefit ratio of specific treatments
for genetic diseases and a more general exception for
“confidential research information,” both of which
were demanded by the state’s major research hospitals
and biotechnology companies. Confidential research
information is specifically defined as follows:
Any results of a genetic test maintained pursuant to pharmacological or clinical research protocols which are subject
to and conducted in accordance with the review and approval of an Institutional Review Board . . . which protects
the confidentiality of the individual who is the subject of
the genetic test either by encryption, encoding or other
means . . . or where the identity of the individual is unknown or protected from disclosure by encrypting or encoding.11

The antidiscrimination provisions prohibit employers, employment agencies, labor organizations, and licensing agencies from discriminating against a person
on the basis of genetic information (e.g., using such
information as a basis for firing or refusing to hire,
represent, or grant membership or a license to the person). In addition, they are not allowed to require genetic testing or the disclosure of the results of genetic
testing; offer an inducement to undergo genetic testing; ask questions about genetic information; use genetic information to affect the terms of a relationship
with the person; or “otherwise seek, receive, or maintain genetic information for non-medical purposes.”11
The provisions governing insurance are more complicated. They basically prohibit medical insurers,
HMOs, and insurance agents from canceling coverage, refusing to issue or renew coverage, or discriminating in any other way on the basis of genetic information. Disability and long-term care insurers may
use genetic information “to set the terms of a policy
provided that such information is reliable information
relating to the insured’s mortality or morbidity, based
on sound actuarial principles, or actual or reasonably
anticipated experience.” Life insurance companies may
ask applicants if they have undergone genetic testing,
but applicants cannot be required to answer this question (although failure to do so may result in an increased rate or denial of coverage). If the applicant has
undergone genetic testing, the results may be used
if they are reliable. This determination is ultimately
made by the insurance commissioner, with the assistance of a special commission to investigate the use of
genetic-test results in connection with the issuance of
life, disability, and long-term care insurance.
To enforce these provisions, the law relies on the
state’s consumer-protection act, which provides for
payment of attorney’s fees and triple damages in the
case of “willful and knowing” violations and also authorizes the attorney general to seek an injunction
against the offending party. However, those measures
will help only persons who incur financial damages

because of a breach of privacy or discrimination, making the law relatively toothless.
DISCRIMINATION ON THE BASIS
OF GENETIC INFORMATION

The ability to discriminate against someone on the
basis of genetic information requires that the information exist. Many people have refused to undergo
genetic testing because of fear that they might lose
their job or insurance coverage or otherwise suffer discrimination.9 That is probably why many commentators have consistently insisted that specific legislation
to prevent genetic discrimination is necessary.13 Because existing state laws differ and not all states have
them, Francis Collins, the director of the National
Human Genome Research Institute, and others have
called for federal legislation to outlaw the use of predictive genetic information by health insurance companies and employers.14 This makes sense.
Under existing law, the federal government can
try to prevent genetic discrimination in employment
through its power to regulate interstate commerce.
The Equal Employment Opportunity Commission has
taken the position that the use of genetic tests to discriminate against workers is a violation of the Americans with Disabilities Act.15 This year, in its first genetics enforcement action, the commission sought to
enjoin the Burlington Northern Santa Fe Railway from
testing some of its employees without consent.16 Burlington Northern was accused of secretly performing
a DNA test that was thought to indicate the presence
or absence of a predisposition to the carpal tunnel syndrome in employees seeking workers’ compensation
or disability payments. Burlington Northern almost
immediately settled the case. The company agreed to
stop genetic testing of its employees. The commission
is continuing its investigation of the initial allegations
and may seek compensatory and punitive damages of
up to $300,000 each for the 20 to 30 workers who
were tested. In a separate lawsuit by the union, which
was dismissed without prejudice, the company also
promised to publicly support federal legislation prohibiting genetic testing in the workplace.17 Nonetheless, the Equal Employment Opportunity Commission
is ill equipped to deal with genetic discrimination in a
systematic way.18
The Massachusetts law ostensibly protects workers
against what Burlington Northern did by prohibiting
employers from seeking, receiving, or maintaining genetic information for nonmedical purposes. But the
employment protection did not help the Burlington
Northern employees, even though the genetic test was
performed in a Massachusetts laboratory, Athena Diagnostics, because the workers were not employed in
Massachusetts. Moreover, even though the genetic test
was performed in a Massachusetts laboratory (which
is covered by the law) without the required certification of the company’s physician that informed consent
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from the workers had been obtained, if the workers
did not incur substantial monetary damages as a result
of this violation they have no real remedy under Massachusetts law. In early July, however, the chief sponsor of the Massachusetts law, Senator Linda Melconian, asked the attorney general to determine whether
Athena Diagnostics violated the law.
Discrimination by insurance companies on the basis
of genetic information is much more complex. Although it could be addressed by federal legislation
governing interstate commerce, insurance has historically been regulated at the state level. This is likely to
remain true for life, disability, and long-term care insurance. Health insurance, however, is more of a necessity than these other forms of insurance. The federal
government has statutory authority to establish antidiscrimination rules for health plans.19 Courts, however, may conclude that because of the Employee Retirement Income Security Act, states have no authority
to regulate discrimination based on genetic information in employer-sponsored group health plans.
PRIVACY OF GENETIC INFORMATION

Genetic privacy is a much broader rubric than genetic discrimination.5,6,20,21 The results of genetic tests
can affect how a person is treated by others, such as
insurers and employers. The person tested, however,
is the one most directly and intimately affected by the
result. The results of genetic tests can change people’s
perceptions of themselves, “their personality, their selfworth, their sense of security, and their relationships
with loved ones.”9 Antidiscrimination legislation, although necessary, is not sufficient to provide protection from these potentially life-changing effects of
genetic testing. Privacy rules are required, such as the
provision in the Massachusetts law that written informed consent be obtained before a genetic test is
performed.
Almost all the definitions of “genetic test” and “genetic information” in state statutes have been criticized
as either too broad or too narrow. One argument is
that all medical information has a genetic basis, so it
is wrong to single out genetic information for special
treatment.22 Another is that laws governing genetic
privacy should apply only to information about DNA
sequences.7 The Massachusetts law represents an intermediate approach. It defines genetic information as
not only DNA, RNA, and information derived from
chromosomes but also the results of protein tests performed “for the purpose of identifying genes” or genetic conditions.
Whether the results of protein tests should be considered genetic information is controversial. Some clinical tests, such as hemoglobin electrophoresis, are protein tests. To many observers, protein tests and gene
tests seem the same. There are reasonable arguments
on both sides. My own view is that, as a practical matter, statutes designed to protect genetic information

should be limited to direct gene-based information,
even though the results of protein or other tests can
sometimes reveal information about DNA sequences
as well. The New York State Task Force on Life and the
Law has taken a different view. In a report on genetic
testing, it concluded that the fact that a test for betaglobin protein could identify the DNA sequence that
caused sickle cell disease was a sufficient reason not to
distinguish between DNA and protein tests.22
For the most part, a person’s DNA does not change
over time. Once physicians or researchers have obtained a DNA sample from a person, they can perform
an innumerable number of new DNA tests on the
sample without ever needing to see the person or obtain another sample. Thus, extensive personal information can be obtained without the person’s knowledge
or consent. Information gleaned from DNA testing is
uniquely private because it can be used to predict (not
determine) a person’s medical status in the future.
PRIVACY AND GENETIC RESEARCH

The Massachusetts law seeks both to protect individual privacy and to promote genetic research. It accomplishes the latter, but only at the expense of the
former, because informed consent is not required in
the case of so-called confidential research information,
as I have discussed. This means that researchers can
use and share the results of genetic testing if their
study protocols have been approved by an institutional review board and if the identity of the subjects is
concealed by encryption, encoding, or other similar
means. In my view, this measure is too vague to be
protective. Researchers should be required to obtain
informed consent for the research use of genetic data
that can be linked to an individual person.
Meaningful protection of privacy in the context of
genetic research also requires that a distinction be
made between genetic information derived from DNA
and the DNA sample itself. Because the DNA sample
can be viewed as a coded medical record, I believe separate rules are needed for DNA samples. One approach
is to require that DNA samples be destroyed or their
identifiers removed as soon as the research for which
consent was provided has been completed. Another is
to require informed consent for the storage of DNA
samples and for any new studies involving the samples
and to give the research subject the right to have the
samples destroyed at any time.7,8 Still another way to
protect the privacy of genetic information is to recognize a person’s property rights with regard to his or her
DNA. Most people understand that ownership usually
means control. Thus, explicit recognition of a person’s
ownership of his or her DNA may make it clear, especially to researchers and biotechnology companies,
that the party with the greatest interest in the information contained in a DNA sample is the person from
whom the sample was obtained and that this person
properly has the right to decide whether and how the
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DNA is used. These and other privacy issues in DNA
research continue to be discussed and debated at both
the national and the international levels, not just at the
state level.6,23,24 Serious penalties for violating a person’s rights with regard to the privacy of genetic information are also needed to make the protection of
these rights meaningful.
CONCLUSIONS

The Massachusetts genetic-testing statute provides
stronger protection against discrimination, especially
in employment, than it does against invasion of privacy. Ultimately, I believe that federal legislation
should address genetic discrimination by employers,
as well as such discrimination by health insurers and
group health plans. President George W. Bush recently announced his support for legislation that will prohibit genetic discrimination on the part of both employers and health insurers.25 In his words, “to deny
employment or insurance to a healthy person based
only on a predisposition [to disease] violates our country’s belief in equal treatment and individual merit.”26
Protection against genetic discrimination by life, disability, and long-term-care insurers should remain the
responsibility of individual states; the Massachusetts
law provides a useful template in this respect. Although
privacy is reasonably protected by requiring that written informed consent be obtained for genetic testing
and the release of test results, in my opinion, the exceptions, particularly for research, are not justified.
I think that specific informed consent should be required. I also believe that the Massachusetts law is
seriously defective in its failure to protect a person’s
privacy rights in the storage and retesting of identifiable DNA samples and in its failure to provide either a strong penalty or an effective remedy for the
violation of these rights.
The privacy of genetic information could continue
to be protected state by state, with each new state law
drawing on the lessons learned by others. As I have
argued elsewhere, however, uniform federal protection
would be more effective.7,8 The experiences of the
states over the past six years provide a reasonable basis
for federal legislation. DNA is not a Nazi code, but
neither is it the language of God. It is highly personal,
private information that may reveal intimate aspects of
a person’s possible medical status in the future. To
protect the privacy of genetic information, we should

limit its creation and dissemination and give people
control over their DNA samples.
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